Indacaterol Once-Daily Provides Sustained 24-h Bronchodilation over 52 Weeks of Treatment in COPD.

Ronald E Dahl; P Kolman; DB Jack; Roger Owen; Benjamin Krämer; Mark Higgins

doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4545

Related publications

Article2018

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

C. Paul, Christopher Em Griffiths, P.C.M. van de Kerkhof, L. Puig, Yves Dutronc, Carsten Henneges, Martín Dossenbach, Kristin Hollister, Kristian Reich

Article2002

Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD

Trevor T. Hansel, Peter J Barnes

Preprint2023

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d'Onorio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Giulia Fiorentini,

Article2023

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino,

Article2005

Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy.

Kristian Reich, F. O. Nestle, Ortonne Jp, Kim Papp, Robert J. Evans, Cynthia Guzzo, Shuangyue Li, L T Dooley, Christopher Em Griffiths